Avatrombopag for the Treatment of Thrombocytopenia After Donor Hematopoietic Stem Cell Transplant
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects and how well avatrombopag works for the
treatment of thrombocytopenia after donor hematopoietic stem cell transplant.
Thrombocytopenia is defined as abnormally low level of platelets in the blood. Avatrombopag
is a small molecule thrombopoietin receptor agonist which stimulates thrombopoietin receptor
leading to increase production of platelets.
Phase:
Phase 2
Details
Lead Sponsor:
Basem William, MD Ohio State University Comprehensive Cancer Center
Collaborators:
Dova Pharmaceuticals National Cancer Institute (NCI)